相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus
Seiki Shirai et al.
FRONTIERS IN IMMUNOLOGY (2020)
Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza
Toshiki Sekiya et al.
VACCINE (2019)
Lipid nanoparticles of Type-A CpG D35 suppress tumor growth by changing tumor immune-microenvironment and activate CD8 T cells in mice
Lisa Munakata et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Giuseppe Del Giudice et al.
SEMINARS IN IMMUNOLOGY (2018)
Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility
Jayesh A. Kulkarni et al.
NUCLEIC ACID THERAPEUTICS (2018)
Adjuvanted influenza vaccines
John S. Tregoning et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides
Hideki Takahashi et al.
FRONTIERS IN IMMUNOLOGY (2018)
Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant
Sarah Schillie et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)
Cationic lipids as one-component vaccine adjuvants: A promising alternative to alum
Malvina Pizzuto et al.
JOURNAL OF CONTROLLED RELEASE (2018)
The Protein Corona as a Confounding variable of nanoparticle-Mediated Targeted vaccine Delivery
Matthias Bros et al.
FRONTIERS IN IMMUNOLOGY (2018)
Nanoparticle Vaccines Against Infectious Diseases
Rashmirekha Pati et al.
FRONTIERS IN IMMUNOLOGY (2018)
Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want
Harm HogenEsch et al.
NPJ VACCINES (2018)
Efficient Targeting and Activation of Antigen Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques
Frank Liang et al.
MOLECULAR THERAPY (2017)
Lipid Nanoparticle Systems for Enabling Gene Therapies
Pieter R. Cullis et al.
MOLECULAR THERAPY (2017)
Allergic Responses induced by the immunomodulatory effects of Nanomaterials upon Skin exposure
Yasuo Yoshioka et al.
FRONTIERS IN IMMUNOLOGY (2017)
Neutrophil swarming and extracellular trap formation play a significant role in Alum adjuvant activity
J. Stephen et al.
NPJ VACCINES (2017)
Modified mRNA Vaccines Protect against Zika Virus Infection
Justin M. Richner et al.
CELL (2017)
Vaccine adjuvants as potential cancer immunotherapeutics
Burcu Temizoz et al.
INTERNATIONAL IMMUNOLOGY (2016)
Beyond antigens and adjuvants: formulating future vaccines
Tyson J. Moyer et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Metal nanoparticles in the presence of lipopolysaccharides trigger the onset of metal allergy in mice
Toshiro Hirai et al.
NATURE NANOTECHNOLOGY (2016)
Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?
Sharan Bobbala et al.
PHARMACEUTICAL RESEARCH (2016)
A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens
Gokul Swaminathan et al.
VACCINE (2016)
A Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human Primates
Gokul Swaminathan et al.
SCIENTIFIC REPORTS (2016)
Co-Administration of Lipid Nanoparticles and Sub-Unit Vaccine Antigens Is Required for Increase in Antigen-Specific Immune Responses in Mice
Elizabeth A. Thoryk et al.
VACCINES (2016)
Adjuvant for vaccine immunotherapy of cancer - focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity
Tsukasa Seya et al.
CANCER SCIENCE (2015)
Critical residues involved in Toll-like receptor 4 activation by cationic lipid nanocarriers are not located at the lipopolysaccharide-binding interface
Caroline Lonez et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity
Geoffrey M. Lynn et al.
NATURE BIOTECHNOLOGY (2015)
Advances in the development of influenza virus vaccines
Florian Krammer et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Expression and Characterization of Recombinant, Tetrameric and Enzymatically Active Influenza Neuraminidase for the Setup of an Enzyme-Linked Lectin-Based Assay
Marua Prevato et al.
PLOS ONE (2015)
Applications of Lipid based Formulation Technologies in the Delivery of Biotechnology-based Therapeutics
Lissinda Plessis et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2014)
Recent progress concerning CpG DNA and its use as a vaccine adjuvant
Hidekazu Shirota et al.
EXPERT REVIEW OF VACCINES (2014)
Recent advances in peptide-based subunit nanovaccines
Mariusz Skwarczynski et al.
NANOMEDICINE (2014)
Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways
Caroline Lonez et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2014)
An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system
Peter M. Moyle et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2013)
Engineering synthetic vaccines using cues from natural immunity
Darrell J. Irvine et al.
NATURE MATERIALS (2013)
Kinetics of the inflammatory response following intramuscular injection of aluminum adjuvant
Fangjia Lu et al.
VACCINE (2013)
Trial Watch Experimental Toll-like receptor agonists for cancer therapy
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2012)
Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine
Elizabeth A. Vasievich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Cationic liposomes as vaccine adjuvants
Dennis Christensen et al.
EXPERT REVIEW OF VACCINES (2011)
Vaccines: the Fourth Century
Stanley A. Plotkin
CLINICAL AND VACCINE IMMUNOLOGY (2009)
Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus
Chih-Jen Wei et al.
JOURNAL OF VIROLOGY (2008)
Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
Paul J. Pockros et al.
JOURNAL OF HEPATOLOGY (2007)
Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration
M Heikenwalder et al.
NATURE MEDICINE (2004)
分享论文
